Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A. Mittendorf, Nadia Harbeck, Andreas Koehler et al.|The Lancet|2020Cited by 1.1k
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast CancerDouglas Yee, Minetta C. Liu, Angela DeMichele et al.|JAMA Oncology|2020Cited by 225
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130H. S. Rugo, Leisha A. Emens, Sherene Loi et al.|Annals of Oncology|2019Cited by 115